Review Article

Omega Class Glutathione S-Transferase: Antioxidant Enzyme in Pathogenesis of Neurodegenerative Diseases

Youngjo Kim,1 Sun Joo Cha,1 Hyun-Jun Choi,1 and Kiyoung Kim1,2

1 Soonchunhyang Institute of Medi-bio Science, Soonchunhyang University, Cheonan 31151, Republic of Korea
2 Department of Medical Biotechnology, Soonchunhyang University, Asan 31538, Republic of Korea

Correspondence should be addressed to Kiyoung Kim; kiyoung2@sch.ac.kr

Received 6 September 2017; Accepted 26 November 2017; Published 24 December 2017

Academic Editor: Sebastien Talbot

Copyright © 2017 Youngjo Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The omega class glutathione S-transferases (GSTOs) are multifunctional enzymes involved in cellular defense and have distinct structural and functional characteristics, which differ from those of other GSTs. Previous studies provided evidence for the neuroprotective effects of GSTOs. However, the molecular mechanisms underpinning the neuroprotective functions of GSTOs have not been fully elucidated. Recently, our genetic and molecular studies using the Drosophila system have suggested that GstO1 has a protective function against H2O2-induced neurotoxicity by regulating the MAPK signaling pathway, and GstO2 is required for the activation of mitochondrial ATP synthase in the Drosophila neurodegenerative disease model. The comprehensive understanding of various neuroprotection mechanisms of Drosophila GstOs from our studies provides valuable insight into the neuroprotective functions of GstOs in vivo. In this review, we briefly introduce recent studies and summarize the novel biological functions and mechanisms underpinning neuroprotective effects of GstOs in Drosophila.

1. Introduction

Glutathione S-transferases (GSTs) are a superfamily of multifunctional isoenzymes involved in the cellular detoxification of several endogenous and exogenous compounds. GSTs catalyze the nucleophilic attack of glutathione (GSH) on the electrophilic centers of substrates, including insecticides, toxic compounds, metabolites, and organic hydroperoxides. GSTs play a crucial role against carcinogens, therapeutic drugs, and various types of cellular oxidative damage [1]. GSTs also regulate the biosynthesis and intracellular transport of hormones [1]. Based on their sequence similarity and substrate specificities, GSTs are subdivided into at least ten subfamilies: alpha, delta, epsilon, kappa, mu, pi, sigma, theta, zeta, and omega [2].

The omega class GST (GSTO) is the most recently defined GST class and a relatively ancient cytosolic enzyme [3, 4]. GSTOs appear to be widespread in nature and have been identified in bacteria, insects, yeast, mammals, and plants [2, 3, 5–7]. GSTO shares low sequence similarity with other GST classes but exhibits the GST fold. GSTO has interesting characteristics compared with those of other GST types. The active sites of GSTOs have a cysteine residue at the N-terminus that can bind to GSH, whereas other GST classes have tyrosine or serine residues in their active sites [8]. GSTOs have distinct enzymatic properties and thiol transferase and dehydroascorbate (DHA) reductase activities, which are similar to reactions catalyzed by thioredoxin and glutaredoxin [3]. There is increasing evidence that GSTOs are also involved in the detoxification of several exogenous stressors. Silkmoth GSTO was induced in the fat body after exposure to several environmental stressors, including bacteria and ultraviolet-B (UV-B) [9]. GSTO3 from the human pathogenic filarial worm Onchocerca volvulus (OvGSTO3) demonstrates stress-resistant effects [10]. Overexpressing GSTO-1 in Caenorhabditis elegans exhibits increased resistance during oxidative damage [11]. In addition, GSTOs were shown to scavenge free radicals by regulating DHA reduction and catalyzing the reduction of inorganic arsenic, monomethylarsonate (MMA), and dimethylarsonate (DMA) [12–14]. In vitro studies have shown that human GSTO1 participates in modulation of the ryanodine receptor,
which is a Ca\(^{2+}\) release channel. In addition, these studies also showed that human GSTO1 is involved in modulation of the signaling pathway during c-Jun N-terminal kinase (JNK)-mediated apoptosis and in the activation of interleukin-1β, an important mediator of inflammatory response [15–17]. Human GSTO1-1 is a novel regulator of lipopolysaccharide- (LPS-) induced inflammatory responses in macrophages and is required for LPS-mediated signaling in macrophages [18, 19].

Recently, an important role for human GSTO1-1 in glutathionylation of the target proteins has been described [17, 20]. β-Actin has been reported to be deglutathionylation by human GSTO1-1 [20]. GSTO1-1 decreased global protein glutathionylation level in macrophages [18]. These findings indicate a critical role for GSTO1 in redox homeostasis through affecting glutathionylation/deglutathionylation of the target proteins. Furthermore, genetic polymorphisms in the human GSTO1 and GSTO2 genes may be associated with the risk of bladder, urothelial, breast, and ovarian cancer [21, 22]. Thus, GSTOs play important roles in decreasing oxidative stress produced by various stressors and cellular processes. Recent studies related to neurodegenerative disorders have implicated polymorphic variants of GSTOs in the age at onset and progression of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) [23–25]. GSTO2 expression levels are decreased in the brains of AD patients. Although GSTO has a protective function against neuronal damage, the molecular mechanisms and physiological functions of GSTOs are still not clear and should be researched further. In this review, we mainly focus on recent studies that have investigated the neuroprotective functions of GSTOs in the Drosophila model system.

2. Omega Class Glutathione S-Transferases in Drosophila

On the basis of the genome sequences and comparative analyses, the Drosophila GST genes can be divided into six subfamilies: delta, epsilon, sigma, omega, zeta, and theta. Drosophila harbors 36 GST genes that encode 41 proteins [2, 26]. Four different GSTO genes in Drosophila are located on chromosome 3L. GSTO genes form a cluster spanning approximately 6kb [2]. This is evidence of internal duplication within the cluster, evolutionally. This duplication gave rise to differentially expressed GSTO isoforms and generated diverse members with differing functionality. These four GSTO genes had been named previously as follows: sepia, GstO1, GstO2, and GstO3 [2]. The sequence identities/similarities are high, at 43–65%/66–82%, based on the amino acid sequence alignment of the different isoforms of GSTO in Drosophila [27]. All isoforms of GSTO have N-terminal extensions and cysteine residues in the active site rather than tyrosine or serine residues, which are found in the active sites of other classes of GSTs. Furthermore, all isoforms of GSTOs have high thiol transferase and DHA reductase activities, characteristic of GSTOs, and low activity toward 1-chloro-2,4-dinitrobenzene (CDNB), a general GST substrate [27]. In addition, the tissue distributions of GSTOs were determined by reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis [27–29]. They have a different tissue distribution in Drosophila. Sepia was found only in the eye. GstO1 and GstO2A were highly expressed in the head and abdomen of adult flies. However, GstO2B and GstO3 were expressed at approximately the same level in all tissues. Therefore, these studies suggest that Drosophila GSTOs might possess tissue-specific physiological functions.

3. Neuroprotective Functions of GSTOs in Drosophila

3.1. GstO1 Has a Protective Function against Neuronal Toxicity. Oxidative stress poses a major threat to organisms living in an aerobic environment and plays a critical role in several neurological disease processes [30]. Oxidative stress is widely implicated in neuronal cell death. Hydrogen peroxide (H\(_2\)O\(_2\)) has been implicated in triggering apoptotic death in several cell types [31, 32]. It may also induce the production of reactive oxygen species (ROS) in neuronal cells. In a recent study, our group determined that GstO1 is highly expressed in the head, and GstO1 mutant flies are sensitive to ROS, produced under H\(_2\)O\(_2\) exposure. Interestingly, H\(_2\)O\(_2\)-induced lethality and apoptotic cell death of neurons in GstO1 mutant flies were suppressed by neuron-specific expression of GstO1. These results suggest that GstO1 has a physiological function in neurons, and GstO1 neuronal expression is sufficient to suppress H\(_2\)O\(_2\)-induced neurotoxicity in GstO1 mutant flies.

Phosphorylation cascades leading to the activation of MAPK, including ERK, JNK, and p38, are among the major cellular signaling pathways known to influence cell survival under ROS damage [33–35]. Several reports have shown that accumulation of ROS in response to H\(_2\)O\(_2\) exposure results in the activation of several stress kinases, involving the ASK1, ERK, and JNK pathways [33–35]. Our studies of H\(_2\)O\(_2\)-induced neurotoxicity in GstO1 mutant flies reveal that increased ERK phosphorylation in GstO1 mutant flies treated with H\(_2\)O\(_2\) was rescued by the expression of GstO1 [28]. The mechanism for the suppression of H\(_2\)O\(_2\)-mediated neurotoxicity appears to be mediated through the suppression of ERK pathway activation. Thus, these findings strongly demonstrate that GstO1 has a critical, protective role against H\(_2\)O\(_2\)-mediated neurotoxicity by regulating the MAPK pathway.

3.2. GstO2 Regulates Complex V Activity in Neurodegenerative Disease. Previous studies have reported that single-nucleotide polymorphisms in human GSTO genes are associated with the age at onset for AD, PD, and stroke [36, 37]. The GSTO1 D140 allele is associated with a decreased risk of familial PD [23]. In addition, a possible relationship between GSTOs loci and the age at onset of amyotrophic lateral sclerosis (ALS) has been reported [38]. These various studies provide evidence that genetic variation of human GSTOs can influence the age at onset of several different neurodegenerative diseases. These studies also suggest that GSTOs may contribute to the pathogenesis of each
Ascorbic acid (AsA), the reduced form of vitamin C, is an essential cofactor in various enzymatic reactions. AsA is an important antioxidant with multiple cellular functions and plays a role in detoxification against endogenous and exogenous stressors. Interestingly, the brain exhibits one of the highest AsA concentrations in the body. AsA concentrations of 1–2 mM have been detected throughout the brain while intracellular concentrations in neuronal cells are much higher, reaching up to 10 mM [14]. This evidence suggests a critical role of AsA in the brain or neuronal cells [40]. Imbalance of AsA homeostasis has also been demonstrated in neurodegenerative diseases such as AD, PD, and ALS. Although most residues in the G-site and H-site of GstOs are well conserved [27], the GstOs have different features, hydrophobicities, shapes, and electrostatic potential distributions [47]. Many research groups have shown that residues in the substrate-binding sites of omega class GST homologues are well conserved across species [48–50]. Although most residues in the G-site and H-site of GstOs in Drosophila are highly conserved [27], the GstOs have different physiological functions in vivo [39, 51]. Therefore, we constructed three-dimensional models of Drosophila GstOs using I-TASSER server and analyzed the surface electrostatic

### 3.3. GstO2 Regulates Ascorbic Acid Recycling

Ascorbic acid (AsA), the reduced form of vitamin C, is an essential cofactor in various enzymatic reactions. AsA is an important antioxidant with multiple cellular functions and plays a role in detoxification against endogenous and exogenous stressors. Interestingly, the brain exhibits one of the highest AsA concentrations in the body. AsA concentrations of 1–2 mM have been detected throughout the brain while intracellular concentrations in neuronal cells are much higher, reaching up to 10 mM [14]. This evidence suggests a critical role of AsA in the brain or neuronal cells [40]. Imbalance of AsA homeostasis has also been demonstrated in neurodegenerative diseases such as AD, PD, and ALS. Although most residues in the G-site and H-site of GstOs are well conserved [27], the GstOs have different features, hydrophobicities, shapes, and electrostatic potential distributions [47]. Many research groups have shown that residues in the substrate-binding sites of omega class GST homologues are well conserved across species [48–50]. Although most residues in the G-site and H-site of GstOs in Drosophila are highly conserved [27], the GstOs have different physiological functions in vivo [39, 51]. Therefore, we constructed three-dimensional models of Drosophila GstOs using I-TASSER server and analyzed the surface electrostatic

#### 4. Structural Difference and Diverse Function of Omega GSTs in Drosophila

Binding of the GSH to GSTs is highly conserved in the N-terminal domain. Substrate-binding sites (H-site) in the C-terminal domain of GSTs are variable with different features, hydrophobicities, shapes, and electrostatic potential distributions [47]. Many research groups have shown that residues in the substrate-binding sites of omega class GST homologues are well conserved across species [48–50]. Although most residues in the G-site and H-site of GstOs in Drosophila are highly conserved [27], the GstOs have different physiological functions in vivo [39, 51]. Therefore, we constructed three-dimensional models of Drosophila GstOs using I-TASSER server and analyzed the surface electrostatic
potential distributions (Figure 1). The electrostatic potential distributions of GstO1, GstO2A, and sepia are similar, with only some differences. In contrast, the electrostatic potential distributions of GstO2B and GstO3 differ markedly from those of the other Drosophila GstO electrostatic potential distributions. These features are likely to be determinants of interactions between Drosophila GstOs and substrates that are still to be discovered. We showed that GstOs have different electrostatic potential distributions and substrate-binding site shapes from each other, by homology modeling analysis. Because these GstO isoforms differ only in the portion of the C-terminal domain that binds the hydrophobic substrate, this region may influence substrate preference. These data may explain the functional differences between each GstO isoform. However, the differences in the functions and catalytic mechanisms of GstOs have not been fully elucidated. Identification of the differences in the structure and electrostatic potential of the GstO substrate-binding sites helped us understand the catalytic role of GstOs in reaction with different substrates and their ability to perform different functions in vivo.

5. Putative Functions of Other GSTOs in Drosophila

Although the in vivo function of Drosophila GstO3 is not yet elucidated, there is some evidence that it may also be involved in antioxidant processes. The GstO3 transcript of Drosophila is expressed at approximately the same level in all tissues. Interestingly, the expression level of GstO3 transcript increased in response to various stressors such as heat shock, heavy metal stress, and exposure to rotenone [52–54]. However, little is known with regard to the exact mechanism responsible for increased GstO3 expression. Thus, GstO3 may have a wide range of antioxidant activities. Further studies are required to understand the physiological function and molecular mechanism by which GstO3 protects cells from various oxidative stressors.

6. Conclusions and Perspective

GSTs are ubiquitously expressed enzymes belonging to the GSH-mediated antioxidant. Sequence alignment analyses revealed that GSTs, including GSTOs, exist in a wide range of organisms. The broad distribution of several GSTs among all living organisms may reflect its important and diverse physiological functions. Particularly, the role exerted by GSTOs in neuronal cells appears to be relevant. Although various studies suggest that oxidative stress plays an important role in the pathogenesis of several human diseases, including neurodegenerative diseases, the exact mechanism of GSTOs in neuroprotective effects against several oxidative stressors that provide a pharmacological basis for the relationship between GstOs and the development of neurodegenerative diseases has not been elucidated. As discussed in this review, our research on Drosophila GstOs has shown that GstOs are involved in protective effects against various neurotoxic conditions. For instance, GstO1 has a protective function against H₂O₂-induced neurotoxicity by regulating the MAPK signaling pathway. In addition, GstO2 is required for the activation of mitochondrial ATP synthase in the Drosophila model of PD. This finding suggests that enhancing the activity of GstO2 in neuronal cells could alleviate neurodegeneration in the Drosophila model of PD. Furthermore, GstO2 has a DHA reductase activity and is required for the recycling of AsA. Thus, GstO2 may play a critical role in the maintenance of AsA concentrations in neuronal cells and plays a protective role against oxidative stress by regulating the AsA recycling pathway in neuronal cells. A comprehensive understanding of various neuroprotection mechanisms of Drosophila GstOs and a further investigation of their pharmacological and antitoxicological properties will enhance our understanding of their role in neuronal cells and the pathogenesis of neurodegenerative diseases.

Previously, our studies provided several evidences for novel diverse roles of GstOs, based on genetic and molecular studies using the Drosophila model system. The C-terminal domain, including the H-site of Drosophila GstOs, is less similar than the N-terminal domain, which contains a cysteine residue in the G-site of GstOs. Thus, the structural differences in the C-terminal domain of GstOs may be responsible for the differences in the functions of various Drosophila GstOs and may influence substrate preference. Further studies are required to identify the in vivo substrates of GSTOs, which are related to neuroprotection, in order to better understand the functional diversity of GSTOs. Because various biological processes are conserved in Drosophila and mammals, we expect that the elucidation of diverse in vivo functions of Drosophila GstOs will have broad biological implications in understanding neuroprotection mechanisms.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education, Science and Technology (MEST) (2014R1A1A2058027; 2017R1D1A1B03035010), the Ministry of Science and ICT (MSIT) (2017R1C1B1008825; 2014R1A1A1037106), and the Soonchunhyang University Research Fund.

References

[1] J. D. Hayes, J. U. Flanagan, and I. R. Jowsey, “Glutathione transferases,” Annual Review of Pharmacology and Toxicology, vol. 45, no. 1, pp. 51–88, 2005.
[2] C. Saisawang, J. Wongantichon, and A. J. Ketterman, “A preliminary characterization of the cytosolic glutathione transferase proteome from Drosophila melanogaster,” Biochemical Journal, vol. 442, no. 1, pp. 181–190, 2012.
[3] P. G. Board, M. Coggan, G. Chelvanayagam et al., “Identification, characterization, and crystal structure of the omega class glutathione transferases,” The Journal of Biological Chemistry, vol. 275, no. 32, pp. 24798–24806, 2000.
[4] P. G. Board, "The omega-class glutathione transferases: structure, function, and genetics," Drug Metabolism Reviews, vol. 43, no. 2, pp. 226–235, 2011.

[5] D. P. Dixon, B. G. Davis, and R. Edwards, "Functional divergence in the glutathione transferase superfamily in plants. Identification of two classes with putative functions in redox homeostasis in Arabidopsis thaliana," The Journal of Biological Chemistry, vol. 277, no. 34, pp. 30859–30869, 2002.

[6] A. Garcera, L. Barreto, L. Piedrafa, J. Tamarit, and E. Herrero, "Saccharomyces cerevisiae cells have three omega class glutathione S-transferases acting as 1-Cys thiol transferases," Biochemical Journal, vol. 398, no. 2, pp. 187–196, 2006.

[7] L. Xun, S. M. Belchik, R. Xun et al., "S-Glutathionyl-(chloro)-hydroquinone reductases: a novel class of glutathione transferases," The Biochemical Journal, vol. 428, no. 3, pp. 419–427, 2010.

[8] P. G. Board and D. Menon, "Glutathione transferases, regulators of cellular metabolism and physiology," Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1830, no. 5, pp. 3267–3288, 2013.

[9] K. Yamamoto, S. Teshiba, Y. Shigeoka et al., "Characterization of an omega-class glutathione S-transferase in the stress response of the silkmoth," Insect Molecular Biology, vol. 20, no. 3, pp. 379–386, 2011.

[10] E. Liebau, J. Hoppenr, M. Muhlmeister et al., "The secretory omega-class glutathione transferase OrGST3 from the human pathogenic parasite Onchocerca volvulus," The FEBS Journal, vol. 275, no. 13, pp. 3438–3453, 2008.

[11] C. Burmeister, K. Luersen, A. Heinick et al., "Oxidative stress in Caenorhabditis elegans: protective effects of the omega class glutathione transferase (GSTO-1)," The FASEB Journal, vol. 22, no. 2, pp. 343–354, 2008.

[12] E. M. Schmuck, P. G. Board, A. K. Whitbread et al., "Characterization of the monomethylarsenate reductase and dehydroascorbate reductase activities of omega class glutathione one transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases," Pharmacogenetics and Genomics, vol. 15, no. 7, pp. 493–501, 2005.

[13] R. A. Zakharyan, A. Sampayo-Reyes, S. M. Healy et al., "Human monomethylarsenic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily," Chemical Research in Toxicology, vol. 14, no. 8, pp. 1051–1057, 2001.

[14] M. E. Rice, "Ascorbate regulation and its neuroprotective role in the brain," Trends in Neurosciences, vol. 23, no. 5, pp. 209–216, 2000.

[15] R. E. Laliberte, D. G. Perregaux, L. R. Hoth et al., "Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1β posttranslational processing," The Journal of Biological Chemistry, vol. 278, no. 19, pp. 16567–16578, 2003.

[16] A. Dulhunty, P. Gage, S. Curtis, G. Chelvanayagam, and P. Board, "The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator," The Journal of Biological Chemistry, vol. 276, no. 5, pp. 3319–3323, 2001.

[17] S. Paul, R. Jakhara, M. Bhardwaj, and S. C. Kang, "Glutathione-S-transferase omega 1 (GSTO1-1) acts as mediator of signaling pathways involved in aflatoxin B1-induced apoptosis-autophagy crosstalk in macrophages," Free Radical Biology & Medicine, vol. 89, pp. 1218–1230, 2015.

[18] D. Menon, R. Coll, L. A. J. O’Neill, and P. G. Board, "Glutathione transferase omega 1 is required for the lipopolysaccharide-stimulated induction of NADPH oxidase 1 and the production of reactive oxygen species in macrophages," Free Radical Biology & Medicine, vol. 73, pp. 318–327, 2014.

[19] D. Menon, R. Coll, L. A. J. O’Neill, and P. G. Board, "GSTO1-1 modulates metabolism in macrophages activated through the LPS and TLR4 pathway," Journal of Cell Science, vol. 128, no. 10, pp. 1982–1990, 2015.

[20] D. Menon and P. G. Board, "A role for glutathione transferase omega 1 (GSTO1-1) in the glutathionylation cycle," The Journal of Biological Chemistry, vol. 288, no. 36, pp. 25769–25779, 2013.

[21] S. B. Marahatta, P. Punyarit, V. Bhudisawasdi, A. Paupairoj, S. Wongkham, and S. Petmitr, "Polymorphism of glutathione S-transferase omega gene and risk of cancer," Cancer Letters, vol. 236, no. 2, pp. 276–281, 2006.

[22] W. Pongstaporn, M. Rochanawutson, S. Wilailak, V. Linasamita, S. Weerakiat, and S. Petmitr, "Genetic alterations in chromosome 10q24.3 and glutathione S-transferase omega 2 gene polymorphism in ovarian cancer," Journal of Experimental & Clinical Cancer Research, vol. 25, no. 1, pp. 107–114, 2006.

[23] M. Allen, F. Zou, H. Chai et al., "Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications," Molecular Neurodegeneration, vol. 7, no. 1, p. 13, 2012.

[24] C. Capurufo, F. Panza, D. Seripa et al., "Polymorphisms in glutathione S-transferase omega-1 gene and increased risk of sporadic Alzheimer disease," Rejuvenation Research, vol. 13, no. 6, pp. 645–652, 2010.

[25] P. G. Board and D. Menon, "Structure, function and disease relevance of omega-class glutathione transferases," Archives of Toxicology, vol. 90, no. 5, pp. 1049–1067, 2016.

[26] A. A. Enayati, H. Ranson, and J. Hemingway, "Insect glutathione transferases and insecticide resistance," Insect Molecular Biology, vol. 14, no. 1, pp. 3–8, 2005.

[27] J. Kim, H. Suh, S. Kim, K. Kim, C. Ahn, and J. Yim, "Identification and characteristics of the structural gene for the Drosophila eye colour mutant sepia, encoding PDA synthase, a member of the omega class glutathione S-transferases," Biochemical Journal, vol. 398, no. 3, pp. 451–460, 2006.

[28] S. Y. Lee, I. A. Lim, G. U. Kang et al., "Protective effect of Drosophila glutathione transferase omega 1 against hydrogen peroxide-induced neuronal toxicity," Gene, vol. 568, no. 2, pp. 203–210, 2015.

[29] K. Kim and J. Yim, "Structural modelling and molecular characterization of omega-class glutathione S-transferase 2 from Drosophila melanogaster," Insect Molecular Biology, vol. 23, no. 3, pp. 357–366, 2014.

[30] I. A. Gamaley and I. V. Klyubin, "Roles of reactive oxygen species: signaling and regulation of cellular functions," International Review of Cytology, vol. 188, pp. 203–255, 1999.

[31] S. Desagher, J. Glowinski, and J. Premont, "Astrocytes protect neurons from hydrogen peroxide toxicity," The Journal of Neuroscience, vol. 16, no. 8, pp. 2553–2562, 1996.

[32] S. Desagher, J. Glowinski, and J. Premont, "Pyruvate protects neurons against hydrogen peroxide-induced toxicity," The Journal of Neuroscience, vol. 17, no. 23, pp. 9060–9067, 1997.
[33] M. H. Cobb, “MAP kinase pathways,” Progress in Biophysics and Molecular Biology, vol. 71, no. 3-4, pp. 479–500, 1999.

[34] V. Adler, Z. Yin, K. D. Tew, and Z. Ronai, “Role of redox potential and reactive oxygen species in stress signaling,” Oncogene, vol. 18, no. 45, pp. 6104–6111, 1999.

[35] K. Z. Guyton, Y. Liu, M. Gorospe, Q. Xu, and N. J. Holbrook, “Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury,” The Journal of Biological Chemistry, vol. 271, no. 8, pp. 4138–4142, 1996.

[36] H. Kolsch, M. Linnebank, D. Lutjohann et al., “Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke,” Neurology, vol. 63, no. 12, pp. 2255–2260, 2004.

[37] Y. J. Li, S. A. Oliveira, P. Xu et al., “Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease,” Human Molecular Genetics, vol. 12, no. 24, pp. 3259–3267, 2003.

[38] E. van de Giessen, I. Fogh, S. Gopinath et al., “Association study on glutathione S-transferase omega-1 and AD,” Amyotrophic Lateral Sclerosis, vol. 9, no. 2, pp. 81–84, 2008.

[39] K. Kim, H. H. Kim, J. Kim, and J. Yim, “Glutathione s-transferase omega 1 activity is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease,” The Journal of Biological Chemistry, vol. 287, no. 9, pp. 6628–6641, 2012.

[40] R. Spector and A. V. Lorenzo, “Ascorbic acid homeostasis in the central nervous system,” The American Journal of Physiology, vol. 225, no. 4, pp. 757–763, 1973.

[41] J. M. May, “Recycling of vitamin C by mammalian thioredoxin reductase,” Methods in Enzymology, vol. 347, pp. 327–332, 2002.

[42] J. X. Wilson, “The physiological role of dehydroascorbic acid,” FEBS Letters, vol. 527, no. 1-3, pp. 5–9, 2002.

[43] D. P. Xu, M. P. Washburn, G. P. Sun, and W. W. Wells, “Purification and characterization of a glutathione dependent dehydroascorbate reductase from human erythrocytes,” Biochemical and Biophysical Research Communications, vol. 221, no. 1, pp. 117–121, 1996.

[44] B. Del Bello, E. Maellaro, L. Sugherini, A. Santucci, M. Comporti, and A. F. Casini, “Purification of NADPH-dependent dehydroascorbate reductase from rat liver and its identification with 3a-hydroxysteroid dehydrogenase,” Biochemical Journal, vol. 304, no. 2, pp. 385–390, 1994.

[45] J. M. May, S. Mendiratta, K. E. Hill, and R. F. Burk, “Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase,” The Journal of Biological Chemistry, vol. 272, no. 36, pp. 22607–22610, 1997.

[46] K. Kiuchi, M. Nishikimi, and K. Yagi, “Purification and characterization of L-gulonolactone oxidase from chicken kidney microsomes,” Biochemistry, vol. 21, no. 20, pp. 5076–5082, 1982.

[47] B. Wu and D. Dong, “Human cytosolic glutathione transferases: structure, function, and drug discovery,” Trends in Pharmacological Sciences, vol. 33, no. 12, pp. 656–668, 2012.

[48] J. Brock, P. G. Board, and A. J. Oakley, “Structural insights into omega-class glutathione transferases: a snapshot of enzyme reduction and identification of a non-catalytic ligandin site,” PLoS One, vol. 8, no. 4, article e60324, 2013.

[49] Y. Zhang, H. Yan, W. Lu, Y. Li, X. Guo, and B. Xu, “A novel omega-class glutathione S-transferase gene in Apis cerana